FAZ-053

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFAZ-053
Drug Alias NameFAZ-053LAE-005LAE005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursTriple Negative Breast NeoplasmsChordoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesLaekna LtdNovartis Pharma Stein AgLaekna Therapeutics Shanghai Co Ltd
Inactive CompaniesNovartis Pharma Ag
Active IndicationsSolid tumoursTriple Negative Breast Neoplasms
Inactive IndicationsChordomaSarcoma, Alveolar Soft Part

Other Information

ATC CodeN/A
Related LinksN/A